Files in this item
ASS234, as a new Multi-Target Directed propargylamine for Alzheimer’s disease therapy
Item metadata
dc.contributor.author | Marco-Contelles, José | |
dc.contributor.author | Unzeta, Mercedes | |
dc.contributor.author | Esteban, Gerard | |
dc.contributor.author | Ramsay, Rona | |
dc.contributor.author | Romero, Alejandro | |
dc.contributor.author | Martínez-Murillo, Ricardo | |
dc.contributor.author | Carreiras, Maria C. | |
dc.contributor.author | Ismaili, Lhassane | |
dc.contributor.author | Bolea, Irene | |
dc.date.accessioned | 2016-06-28T09:30:09Z | |
dc.date.available | 2016-06-28T09:30:09Z | |
dc.date.issued | 2016-06-28 | |
dc.identifier | 243265429 | |
dc.identifier | 0d6a6aed-4e11-4942-ad84-825d8a1eb309 | |
dc.identifier | 84980396145 | |
dc.identifier | 000379394400001 | |
dc.identifier.citation | Marco-Contelles , J , Unzeta , M , Esteban , G , Ramsay , R , Romero , A , Martínez-Murillo , R , Carreiras , M C , Ismaili , L & Bolea , I 2016 , ' ASS234, as a new Multi-Target Directed propargylamine for Alzheimer’s disease therapy ' , Frontiers in Neuroscience , vol. 10 , 294 . https://doi.org/10.3389/fnins.2016.00294 | en |
dc.identifier.issn | 1662-453X | |
dc.identifier.uri | https://hdl.handle.net/10023/9054 | |
dc.description | MU and JMC thank MINECO (Spain) for support (Grant SAF2012-33304; SAF2015-65586-R). RRR, MU, GE and JMC thank EU (COST Action 1103) for support. | en |
dc.description.abstract | The complex nature of Alzheimer’s disease (AD) has prompted the design of Multi-Target-Directed Ligands (MTDL) able to bind to diverse biochemical targets involved in the progress and development of the disease. In this context, we have designed a number of MTD propargylamines showing antioxidant, anti-betaamyloid, anti-inflammatory, as well as cholinesterase and monoamine oxidase inhibition capacities. Here, we describe these properties in the MTDL ASS234, our lead-compound ready to enter in pre-clinical studies for AD, as a new multipotent, permeable cholinesterase/monoamine oxidase inhibitor, able to inhibit Aβ- aggregation, possessing antioxidant and neuroprotective properties. | |
dc.format.extent | 7 | |
dc.format.extent | 428670 | |
dc.language.iso | eng | |
dc.relation.ispartof | Frontiers in Neuroscience | en |
dc.subject | Multi-target directed ligands, | en |
dc.subject | Alzheimer’s disease | en |
dc.subject | Monomaine oxidases | en |
dc.subject | Cholinesterases | en |
dc.subject | Drugs | en |
dc.subject | RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry | en |
dc.subject | RA Public aspects of medicine | en |
dc.subject.lcc | RC0321 | en |
dc.subject.lcc | RA | en |
dc.title | ASS234, as a new Multi-Target Directed propargylamine for Alzheimer’s disease therapy | en |
dc.type | Journal item | en |
dc.contributor.sponsor | European Commission | en |
dc.contributor.institution | University of St Andrews. School of Biology | en |
dc.contributor.institution | University of St Andrews. Biomedical Sciences Research Complex | en |
dc.identifier.doi | 10.3389/fnins.2016.00294 | |
dc.description.status | Peer reviewed | en |
dc.identifier.grantnumber | oc-2010-2-8526 | en |
This item appears in the following Collection(s)
Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.